Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).

The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health an
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, Inc. ... develops novel diagnostics to personalize and advance the treatment ... Gregory T. Lucier as chairman of Epic,s ... CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins ... commercializes its circulating rare cell analysis platform with special ...
(Date:7/30/2014)... July 30, 2014 NCERC at ... will present his findings on corn stover pretreatment ... this week in Washington, D.C. , “Arun’s ... conference is a testament to the success of ... said. “Thanks to the foresight and vision of ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Aug. 7 SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced ... 30, 2008. For the three months ended June 30, 2008, ... of $7.2 million. For,the six months ended June 30, 2008, ... The revenue in the six month period includes $10.8,million of ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... (the "Arrangement Agreement") dated,August 6, 2008 with, among ... Chromos, and Modatech Systems Inc. ("Modatech"),pursuant to which ... effect a plan,of arrangement (the "Arrangement") under section ...
Cached Biology Technology:SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3
(Date:7/30/2014)... the shortest distance between two points is a straight ... have been taking the familiar axiom to heart. ... to be intense, with each racing for the chance ... species, sperm form cooperative groups that allow them to ... A new study, conducted by Heidi Fisher, a post-doctoral ...
(Date:7/30/2014)... San Antonio Life Sciences Institute (SALSI), a joint venture ... and The University of Texas Health Science Center at ... Initiative Pilot Program. The winners, Emily Boice from UTSA ... receive $25,000 for their project titled, "Novel engineered ferritins ... environment." , Boice and Huang,s research is focused on ...
(Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... New Zealand snail and its worm parasite makes sex ... in the absence of parasites, say Indiana University Bloomington ... week,s Current Biology . The scientists, report ... of sex, which suggests sexual reproduction allows host species ...
... external skeletons that appear to change colors as the ... for something else--providing a blueprint for materials that reflect ... Scientists at the Georgia Institute of Technology in Atlanta ... light-reflecting properties of the cells that make up their ...
... -- Experiencing chronic stress day after day can produce wear ... have a detrimental effect on learning and emotion. However, ... learning and memory. Researchers at the University at Buffalo ... that acute stress can produce a beneficial effect on learning ...
Cached Biology News:Parasitic worms make sex worthwhile 2Parasitic worms make sex worthwhile 3What scientists know about jewel beetle shimmer 2Short stressful events may improve working memory 2
... is a molecular screening, low melting point ... sieving. It is recommended for separation of ... such as PCR products. Micro ABgarose is ... not recommended for blotting techniques. At a ...
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
Biology Products: